However, SREBP1 (the more significant transcription element controlling de novo lipogenesis in the liver and a significant aspect in NAFLD pathogenesis) is negatively regulated by FoxO1, which inhibits lipogenesis, resulting in a decrease in excess fat and optimizing NAFLD therapy [141]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.